Publication Name	World Journal of Diabetes
Manuscript ID	92389
Country	China

Category	Endocrinology & Metabolism
Manuscript Type	Meta-Analysis
Article Title	Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Lan Ma, Dan Ge and Xue-Jian Hu
Funding Agency and Grant Number
Corresponding Author	Xue-Jian Hu, MM, Doctor, Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Lanzhou University, No. 82 Linxia Road, Lanzhou 730000, Gansu Province, China. xuejian2023@sina.com
Key Words	Type-1 diabetes mellitus; Teplizumab; Anti-CD3 monoclonal antibody; Insulin; Glycated haemoglobin A1c; C-peptide
Core Tip	Type 1 diabetes mellitus (T1DM) may benefit from teplizumab. However, there is limited data on its long-term effects on clinical T1DM development, safety, and efficacy. Given its perceived use, this research evaluated the effectiveness and safety of teplizumab for T1DM patients through a systematic review and meta-analysis of 8 randomized controlled trials, including 1908 patients from various age groups. It was found that teplizumab treatment results in reduced insulin use, improved C-peptide response, significant glycated haemoglobin A1c changes in T1DM patients with minimal side effects and improved glycaemic management.
Citation	Ma XL, Ge D, Hu XJ. Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis. World J Diabetes 2024; In press

Received	2024-01-24 07:29
Peer-Review Started	2024-01-24 07:29
To Make the First Decision
Return for Revision	2024-02-27 04:08
Revised	2024-03-05 08:54
Second Decision	2024-04-23 23:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-04-30 09:48
Articles in Press	2024-04-30 09:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com